Nasdaq grts.

If you want to know who really controls Gritstone bio, Inc. (NASDAQ:GRTS), then you'll have to look at the makeup of its share registry. We can see that retail investors own the lion's share in the company with 43% ownership. ... NasdaqGS:GRTS Earnings and Revenue Growth October 6th 2023. Our data indicates that hedge funds own 16% of …Nov 10, 2023 · During the recent session, Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares were 0.46 million, with the beta value of the company hitting 0.56. At the last check today, the stock’s price was $1.46, reflecting an intraday loss of -6.73% or -$0.1. The 52-week high for the GRTS share is $4.05, that ... EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Aug 1, 2023 · Financials. GRTS has a market cap of $169mn and a cash balance of $153mn. Research and development expenses were $30.5 million for the three months ended March 31, 2023 while general and ...

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

EMERYVILLE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next …WebGritstone bio stock quote and GRTS charts. Latest stock price today and the US's most active stock market forums.

Gracell Biotechnologies Inc. (NASDAQ:GRCL), Blue Ridge Bankshares, Inc. (NYSE:BRBS), Gritstone bio, Inc. (NASDAQ:GRTS), and Ebix, Inc. (NASDAQ:EBIX) are some best stocks for day trading. Click ...So spare a thought for the long term shareholders of Gritstone bio, Inc. (NASDAQ:GRTS); the share price is down a whopping 70% in the last three years. That might cause some serious doubts about ...EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the …WebGritstone bio, Inc. Common Stock (GRTS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.WebGRTS Gritstone bio Inc Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine

GRTS technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Gritstone bio, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more.

May 11, 2023 · First Quarter 2023 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $153.2 million as of March 31, 2023, compared to $185.2 million as of December 31, 2022 ...

EMERYVILLE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Nov 21, 2023 · Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ... About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. May 6, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone Bio Inc (NASDAQ:GRTS) trade information. Upright in the red during last session for losing -4.86%, in the last five days GRTS remained trading in the red while hitting it’s week-highest on Friday, 11/10/23 when the stock touched $1.37 price level, adding 14.27% to its value on the day.EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Find the latest news headlines from Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.

Find the latest analyst research for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com. Gritstone bio, Inc. Common Stock (GRTS) Analyst Research | Nasdaq …WebThe company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Price Target Upside/Downside. According to ...Today’s penny stock pick is the clinical-stage biotechnology company, Gritstone bio, Inc. (NASDAQ: GRTS). Gritstone bio, Inc. engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase …Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Gritstone bio, Inc. Common Stock (GRTS) Pre-Market Stock Quotes - Nasdaq offers ...See the latest Gritstone Bio Inc stock price (GRTS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Web

Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation May 26. Consensus revenue estimates increase to US$46.1m May 13. First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020) May 07. Gritstone Oncology EPS beats by $0.41, beats on revenue6 ธ.ค. 2564 ... (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI ...Financials. GRTS has a market cap of $169mn and a cash balance of $153mn. Research and development expenses were $30.5 million for the three months ended March 31, 2023 while general and ...Find the latest on short interest for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.WebJul 15, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation May 26. Consensus revenue estimates increase to US$46.1m May 13. First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020) May 07. Gritstone Oncology EPS beats by $0.41, beats on revenueNov 21, 2023 · Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ...

Find the latest on short interest for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.

EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

GRTS Historical Data. Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online . The net and ...Follow. EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines ...Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer ...EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by ...Celebrations may be in order for Gritstone bio, Inc. (NASDAQ:GRTS) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Nov 24, 2023 · Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ... EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Gritstone bio, Inc. (GRTS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 1.3100 -0.0100 (-0.76%) As of 03:13PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y As of August 31, 2023, the average one-year price target for Gritstone Bio is 8.77. The forecasts range from a low of 2.02 to a high of $21.00. The average price target represents an increase of ...Mar 21, 2023 · Gritstone bio, Inc. is a clinical-stage biotechnology company headquartered just outside of San Francisco. The company is focused on developing vaccine-based immunotherapy candidates against ... Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Instagram:https://instagram. otckxotcmkts fgphfmoneylion scamforex charting software Vaccine-developer Gritstone bio ( NASDAQ: GRTS) trended higher on Tuesday after B. Riley launched its coverage with a Buy rating and a 12-month target of $8 per share, noting its prospects in ...Jun 3, 2021 · The Last 12 Months Of Insider Transactions At Gritstone bio. The Executive VP & CTO, Roman Yelensky, made the biggest insider sale in the last 12 months. That single transaction was for US$221k ... electric vehicle battery stockgood day trading penny stocks Nov 27, 2023 · The latest price target for Gritstone Bio ( NASDAQ: GRTS) was reported by Piper Sandler on Thursday, September 28, 2023. The analyst firm set a price target for 7.00 expecting GRTS to rise to ... maybach eqs EMERYVILLE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...During the recent session, Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares were 0.46 million, with the beta value of the company hitting 0.56. At the last check today, the stock’s price was $1.46, reflecting an intraday loss of -6.73% or -$0.1. The 52-week high for the GRTS share is $4.05, that ...